Navigation Links
Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate
Date:9/8/2009

SOMERSET, N.J., Sept. 8 /PRNewswire/ -- Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090908/NY71560 )

"Insomnia is a serious and common medical problem that affects tens of millions of Americans," said Sharon S. Clarke, president and general manager of Meda. "With the introduction of EDLUAR sublingual tablets, patients with insomnia who have trouble falling asleep now have another treatment option. We are pleased to be the company that brings this innovative new formulation to these patients."

According to a "Sleep in America" poll conducted by the National Sleep Foundation, one in five people surveyed reported difficulty falling asleep at least a few nights a week.(1)

"Insomnia is a complex problem because patients can present with a variety of troubling symptoms," said Harry Sacks, M.D., vice president, medical affairs of Meda. "EDLUAR combines the efficacy and safety profile of zolpidem tartrate -- an agent used for 17 years -- with a new sublingual formulation that is convenient for patients with short-term insomnia whose primary complaint is the inability to fall asleep."

EDLUAR sublingual tablets contain the active ingredient zolpidem tartrate and have a pharmacokinetic profile characterized by rapid absorption. EDLUAR offers simple and convenient administrat
'/>"/>

SOURCE Meda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Rodgers Introduces SamarionSolution to International Audience
2. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
3. Emerson Ecologics Introduces the Emerson Quality Partner(TM) Program
4. Nuvilex Introduces Last Shot Hangover Remedy(TM) Video
5. EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors
6. American Community Introduces Latitude(TM) Health Plan for Employer Groups in Nebraska
7. Confidential Online STD Testing Clinic, getSTDtested.com, Introduces Edu-Tainment for STD Prevention as Social Networking Changes Dating Scene
8. babyUV/kidsUV inc. Introduces Its kidsUV Surf Team Line of Sun Protection Swim Wear
9. ConnextionsHealth Introduces Turnkey, Rapid Ramp Call Verification Solution
10. Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing
11. Verizon Introduces New IT Security Capabilities for Health Care Industry
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Microsoft Rogue Internet Pharmacy Problem Fixed 3F Not So Fast Say Researchers 54512 1Microsoft Rogue Internet Pharmacy Problem Fixed 3F Not So Fast Say Researchers 54512 2Orchids and fungi partners for life 9571 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2